期刊文献+

2006—2009年解放军总医院调节血脂药应用分析

Utilization of Antilipemic Agents in Chinese PLA General Hospital During 2006-2009
下载PDF
导出
摘要 目的:分析我院调节血脂药应用情况,为临床合理用药提供参考。方法:对我院2006—2009年调节血脂药的用药金额、用药频度(DDDs)、限定日费用(DDC)等进行统计分析。结果:他汀类为我院使用最为广泛的药物,辛伐他汀、阿托伐他汀钙分别居销售金额的前2位,瑞舒伐他汀成为使用增长最快的药物。DDDs排序前5位药品为辛伐他汀、阿托伐他汀钙、氟伐他汀、非诺贝特、阿昔莫司。结论:我院调节血脂药的使用基本合理,符合调节血脂药的国内应用趋势。 OBJECTIVE: To analyze the utilization of antilipemic drugs in our hospital so as to provide references for rational use of antilipemic drugs.METHODS: The utilization of antilipemic drugs in our hospital during 2006-2009 was analyzed in respect of the consumption sum,DDDs and DDC.RESULTS: Statins was predominantly used antilipemic drugs in our hospital,with simvastatin and atorvastatin calcium dominating the top 2 places in respect of consumption sum.The consumption sum of rosuvastatin witnessed the most rapid increase.In terms of DDDs,simvastatin,atorvastatin,fluvastatin,fenofibrate and acipimox took the first 5 places among all the antilipemic drugs.CONCLUSION: The use of antilipemic drugs in our hospital was basically rational and which is consistent with the utilization tendency of antilipemic drugs.
出处 《中国医院用药评价与分析》 2012年第7期582-584,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 调节血脂药 用药频度 限定日费用 用药分析 Antilipemic drugs; DDDs; DDC; Analysis of drug utilization
  • 相关文献

参考文献2

二级参考文献42

  • 1ORDOVAS J M, LOPEZ-MIRANDA J, PEREZ-JIMENEZ F, et al. Effect of apolipoprotein E and A-Ⅳ phenotypes on the low density lipoprotein response to HMG-CoA reductase inhibitor therapy [ J ]. Atherosclerosis, 1995,113 ( 2 ) : 157 - 166.
  • 2OJALA J P, HELEBE E, EHNHOLM C, et al. Effecet of apolipoprotein E polymorphism and Xbal polyoirohism of apolipoprotein B on response to lobastatin treatment in familial and non-familial hypercholesterolaemia [ J ]. J Intern Med, 2001, 230 : 397 - 405.
  • 3PEDRO-BOTET J, SCHAEFER E J, BAKKER-ARKEMA R G, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner [ J ]. Atherosclerosis, 2001, 158 ( 1 ) : 183-193.
  • 4GERDES L U, GERDES C, KERVINEN K,et al. The apolipoprotein 4 Allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the scandinavian simvastatin survival study [ J ]. Circulation, 2000, 101 ( 12 ):1366-1371.
  • 5BALLANTYNE C M, HERD J A, STEIN E A, et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy[J]. J Am Coll Cardiol, 2000, 36 (5) : 1572-1578.
  • 6GERDES L U, GERDES C,KERBINEN K, et al. The apolipoprotein epsilon 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarctiokn: a substudy of the Scandinavian simvastatin survival study [J]. Circulation, 2000, 101 (12) :1366 - 1371.
  • 7HOFFMANN M M, WINKELMANN B R, WIELAND H, et al. The significance of genetic polymorphisms in modulating the response to lipid-lowering drugs[J]. Pharmacogenomics ,2001,2 ( 2 ) : 107 - 121.
  • 8KUIVENHOVEN J A,JUKEMA J W,ZWINDWEMAN A H, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis [ J ]. N Engl J Med,1998,338(2) :86 -91.
  • 9CARLQUIST J F, MUHLESTEIN J B, HORNE B D. The cholesteryl ester transfer protenin Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease [ J ]. Am Hear J, 2003,146 ( 6 ) : 1007 - 1014.
  • 10ROSES A D. Pharmacogenetics and drug development: the path to safer and more effective drugs [ J ]. Nat Rev Genet, 2004, 5 ( 9 ) : 645 - 656.

共引文献353

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部